Akebia Therapeutics, Inc.(AKBA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AKBA Akebia Therapeutics, Inc.

盘后交易 05-22 16:03:27 EDT

1.02

+0.00

0.00%

盘后1.02

+0.000.00%

16:01 EDT

最高1.05	最低1.00	成交量231.33万
今开1.01	昨收1.02	日振幅4.90%
总市值2.73亿	流通市值2.65亿	总股本2.68亿
成交额235.36万	换手率0.89%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AKBA","market":"US","secType":"STK","nameCN":"Akebia Therapeutics, Inc.","latestPrice":1.02,"timestamp":1779480000000,"preClose":1.02,"halted":0,"volume":2313284,"hourTrading":{"tag":"盘后","latestPrice":1.02,"preClose":1.02,"latestTime":"16:01 EDT","volume":20348,"amount":20754.96,"timestamp":1779480106271,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":259801013,"shares":267879239,"eps":-0.077739,"marketStatus":"盘后交易","change":0,"latestTime":"05-22 16:03:27 EDT","open":1.01,"high":1.05,"low":1,"amount":2353621.1957648,"amplitude":0.04902,"askPrice":1.07,"askSize":6089,"bidPrice":1.01,"bidSize":3185,"shortable":3,"etf":0,"ttmEps":-0.077739,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779494400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1395288000000,"exchange":"NASDAQ","adjPreClose":1.02,"preHourTrading":{"tag":"盘前","latestPrice":1.03,"preClose":1.02,"latestTime":"09:04 EDT","volume":3568,"amount":3640.5181728,"timestamp":1779455043327,"change":0.01,"changeRate":0.009804,"amplitude":0.019608},"postHourTrading":{"tag":"盘后","latestPrice":1.02,"preClose":1.02,"latestTime":"16:01 EDT","volume":20348,"amount":20754.96,"timestamp":1779480106271,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.225547,"impliedVol":0.7024,"impliedVolPercentile":0.259},"requestUrl":"/m/hq/s/AKBA","defaultTab":"news","newsList":[{"id":"1182427273","title":"Akebia Therapeutics公司AKB-097将于2026年下半年启动针对罕见肾脏疾病的II期篮子试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1182427273","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182427273?lang=zh_cn&edition=full","pubTime":"2026-04-13 20:05","pubTimestamp":1776081936,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics公司近日宣布，其研发药物AKB-097计划于2026年下半年进入针对罕见肾脏疾病的II期篮子试验阶段。该试验旨在评估AKB-097在多种罕见肾病患者群体中的疗效与安全性，标志着公司在肾脏疾病治疗领域的重要进展。\n篮子试验设计允许在同一试验框架下同时研究药物对多种疾病亚型的效果，有望加速罕见病治疗方案的开发进程。此次试验的推进，将为进一步验证AKB-097的临床潜力提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKBA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191983131","title":"Akebia Therapeutics任命生物制药领域领袖Philip Vickers博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1191983131","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191983131?lang=zh_cn&edition=full","pubTime":"2026-04-02 04:06","pubTimestamp":1775074009,"startTime":"0","endTime":"0","summary":"生物制药企业Akebia Therapeutics, Inc. (NASDAQ: AKBA) 宣布，正式任命行业资深专家Philip Vickers博士为公司董事会新成员。Vickers博士在生物医药研发及企业管理领域拥有深厚经验，他的加入预计将为公司战略发展及创新管线推进注入重要动能。此次人事变动即日生效，标志着Akebia Therapeutics在强化治理结构、吸纳跨界人才方面的持续布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180523709","title":"Akebia Therapeutics公布2025年第四季度及全年财务业绩与商业管线进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1180523709","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180523709?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:14","pubTimestamp":1772108040,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics, Inc.  今日正式披露了其2025财年第四季度及全年的财务报告，同时重点介绍了公司在商业化进程与研发管线方面的最新动态。此次公布的财务数据与业务亮点，为投资者及市场参与者提供了评估公司价值与未来方向的关键依据。财务业绩方面，公司详细公布了第四季度及全年的营收、利润及现金流等关键指标。商业化进展部分，则着重介绍了已上市产品的市场表现、市场拓展策略以及患者可及性方面的成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167881747","title":"Akebia Therapeutics宣布首例患者接受Praliciguat治疗局灶节段性肾小球硬化症的二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1167881747","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167881747?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:02","pubTimestamp":1767704560,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics, Inc.（股票代码：AKBA）已宣布，其候选药物Praliciguat在治疗局灶节段性肾小球硬化症（FSGS）的二期临床试验中，首位患者已完成首次给药。这一进展标志着该药物在针对这一罕见肾脏疾病的临床开发进程中迈出了关键一步。Praliciguat作为一种可溶性鸟苷酸环化酶激动剂，旨在通过改善肾脏微循环来缓解疾病进展。此次二期试验将评估其安全性、耐受性及初步疗效，为后续研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKBA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132614643","title":"Akebia Therapeutics Inc：已在局灶节段性肾小管硬化症（FSGS）中启动Praliciguat的第二阶段试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1132614643","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132614643?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:05","pubTimestamp":1764590739,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc：已在局灶节段性肾小管硬化症（FSGS）中启动Praliciguat的第二阶段试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB","AKBA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140785237","title":"Akebia Therapeutics：计划进行2期临床篮子试验，以评估补体抑制剂在多种罕见肾病适应症中的效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1140785237","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140785237?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:05","pubTimestamp":1764590738,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics：计划进行2期临床篮子试验，以评估补体抑制剂在多种罕见肾病适应症中的效果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","AKBA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177212605","title":"Akebia Therapeutics：从Q32 Bio收购下一代组织靶向C3d-Factor H融合蛋白补体抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1177212605","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177212605?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:03","pubTimestamp":1764590607,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics：从Q32 Bio收购下一代组织靶向C3d-Factor H融合蛋白补体抑制剂","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKBA","QTTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514038944","title":"Akebia Therapeutics, Inc.盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038944","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514038944?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:12","pubTimestamp":1740669173,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时12分，Akebia Therapeutics, Inc.股票出现波动，股价急速拉升5.00%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体涨幅为0.72%。其相关个股中，Ironwood医药、Optinose, Inc.、基立福涨幅较大，Petros Pharmaceuticals, Inc.、苏轩堂、Quantum Biopharma Ltd.较为活跃，换手率分别为23.43%、12.19%、6.32%，振幅较大的相关个股有Petros Pharmaceuticals, Inc.、Cyclo Therapeutics Inc C/Wts 11/12/2025、Quantum Biopharma Ltd.，振幅分别为23.11%、20.58%、20.28%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227231253abdf79aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227231253abdf79aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKBA","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513169202","title":"Akebia Therapeutics, Inc.盘中异动 下午盘股价大跌5.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513169202","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513169202?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:26","pubTimestamp":1740162384,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日02时26分，Akebia Therapeutics, Inc.股票出现波动，股价大幅跳水5.50%。截至发稿，该股报1.81美元/股，成交量175.929万股，换手率0.81%，振幅7.33%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体涨幅为1.31%。其相关个股中，Sunshine Biopharma Inc C/Wts 、大自然药业、Therapeuticsmd, Inc.涨幅较大，大自然药业、Therapeuticsmd, Inc.、Petros Pharmaceuticals, Inc.较为活跃，换手率分别为4252.01%、105.48%、34.98%，振幅较大的相关个股有大自然药业、Sunshine Biopharma Inc C/Wts 、Therapeuticsmd, Inc.，振幅分别为118.46%、63.34%、62.87%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222022624962baffc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222022624962baffc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKBA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508149384","title":"Akebia Therapeutics, Inc.盘中异动 早盘股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508149384","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508149384?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:32","pubTimestamp":1738593153,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时32分，Akebia Therapeutics, Inc.股票出现波动，股价大幅跳水5.09%。截至发稿，该股报2.13美元/股，成交量11.9169万股，换手率0.05%，振幅1.34%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体跌幅为0.30%。其相关个股中，脑再生科技、大自然药业、Incannex Healthcare Inc.涨幅较大，Inmed Pharmaceuticals Inc.、Painreform Ltd.、苏轩堂较为活跃，换手率分别为28.80%、4.13%、1.59%，振幅较大的相关个股有Ironwood医药、苏轩堂、Canopy Growth Corporation，振幅分别为5.13%、4.88%、4.52%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223233abc106f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223233abc106f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKBA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505024274","title":"Akebia Therapeutics, Inc.盘中异动 早盘股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505024274","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505024274?lang=zh_cn&edition=full","pubTime":"2025-01-21 22:36","pubTimestamp":1737470191,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时36分，Akebia Therapeutics, Inc.股票出现异动，股价快速拉升5.07%。截至发稿，该股报2.18美元/股，成交量47.3209万股，换手率0.22%，振幅5.80%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体涨幅为0.68%。其相关个股中，Inmed Pharmaceuticals Inc.、Evolus, Inc. Common Stock、Im Cannabis Corp.涨幅较大，Inmed Pharmaceuticals Inc.、大自然药业、Cbdmd, Inc.较为活跃，换手率分别为1859.59%、3.15%、2.61%，振幅较大的相关个股有Akanda Corp.、Flora Growth Corp.、Amneal Pharmaceuticals, Inc.，振幅分别为105.06%、104.15%、101.94%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121223631986e33ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121223631986e33ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKBA","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504118780","title":"Akebia Therapeutics, Inc.盘中异动 大幅拉升5.44%报2.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504118780","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504118780?lang=zh_cn&edition=full","pubTime":"2025-01-18 02:10","pubTimestamp":1737137404,"startTime":"0","endTime":"0","summary":"北京时间2025年01月18日02时10分，Akebia Therapeutics, Inc.股票出现异动，股价快速上涨5.44%。截至发稿，该股报2.04美元/股，成交量428.997万股，换手率1.97%，振幅5.70%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体跌幅为1.49%。其相关个股中，Im Cannabis Corp.、Inmed Pharmaceuticals Inc.、和黄医药涨幅较大，Cbdmd, Inc.、大自然药业、Painreform Ltd.较为活跃，换手率分别为21.31%、14.10%、10.91%，振幅较大的相关个股有Cbdmd, Inc.、Alvotech C/Wts 、Aytu Biopharma, Inc.，振幅分别为21.41%、15.00%、12.44%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118021004a225ec1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118021004a225ec1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","AKBA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503628678","title":"Akebia Therapeutics, Inc.盘中异动 早盘股价大涨5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503628678","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503628678?lang=zh_cn&edition=full","pubTime":"2025-01-15 23:03","pubTimestamp":1736953420,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日23时03分，Akebia Therapeutics, Inc.股票出现异动，股价急速上涨5.25%。截至发稿，该股报1.99美元/股，成交量39.8299万股，换手率0.18%，振幅3.47%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体涨幅为0.67%。其相关个股中，Therapeuticsmd, Inc.、Alvotech C/Wts 、博美集团涨幅较大，大自然药业、Cbdmd, Inc.、Intra-Cellular Therapies Inc.较为活跃，换手率分别为16.48%、6.00%、2.33%，振幅较大的相关个股有Talphera, Inc.、坎伯兰药业、苏轩堂，振幅分别为11.86%、10.49%、9.79%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152303409867444f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152303409867444f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","AKBA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503501704","title":"HC Wainwright & Co.：重申Akebia Therapeutics(AKBA.US)评级，由买入调整至买入评级, 目标价由7.50美元调整至7.50美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503501704","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503501704?lang=zh_cn&edition=full","pubTime":"2025-01-15 01:22","pubTimestamp":1736875351,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Akebia Therapeutics(AKBA.US)评级，由买入调整至买入评级, 目标价由7.50美元调整至7.50美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15012247459144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AKBA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503858503","title":"Akebia Therapeutics, Inc.盘中异动 急速上涨5.14%报1.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503858503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503858503?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:56","pubTimestamp":1736780184,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时56分，Akebia Therapeutics, Inc.股票出现异动，股价快速拉升5.14%。截至发稿，该股报1.84美元/股，成交量64.8217万股，换手率0.30%，振幅7.14%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体跌幅为1.03%。其相关个股中，Biofrontera Inc C/Wts 27/10/2026 、Intra-Cellular Therapies Inc.、脑再生科技涨幅较大，Intra-Cellular Therapies Inc.、大自然药业、Cbdmd, Inc.较为活跃，换手率分别为10.74%、7.82%、4.77%，振幅较大的相关个股有Citius Oncology, Inc.、正业生物、Biofrontera Inc.，振幅分别为17.39%、11.05%、9.82%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132256259864daa7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132256259864daa7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKBA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2495030165","title":"Akebia Therapeutics, Inc.盘中异动 临近收盘股价大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2495030165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495030165?lang=zh_cn&edition=full","pubTime":"2024-12-31 05:01","pubTimestamp":1735592463,"startTime":"0","endTime":"0","summary":"北京时间2024年12月31日05时01分，Akebia Therapeutics, Inc.股票出现异动，股价急速下挫5.13%。截至发稿，该股报1.85美元/股，成交量187.925万股，换手率0.86%，振幅4.62%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体跌幅为0.92%。其相关个股中，Emergent Biosolutions Inc.、Biofrontera Inc C/Wts 27/10/2026 、Scilex Holding Company涨幅较大，大自然药业、Painreform Ltd.、苏轩堂较为活跃，换手率分别为37.39%、24.02%、14.37%，振幅较大的相关个股有Biofrontera Inc C/Wts 27/10/2026 、Alvotech C/Wts 、Scilex Holding Company，振幅分别为40.56%、30.96%、23.10%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231050103985570fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231050103985570fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","AKBA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492159353","title":"Akebia Therapeutics, Inc.盘中异动 急速下挫5.08%报1.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492159353","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492159353?lang=zh_cn&edition=full","pubTime":"2024-12-19 04:26","pubTimestamp":1734553585,"startTime":"0","endTime":"0","summary":"北京时间2024年12月19日04时26分，Akebia Therapeutics, Inc.股票出现异动，股价快速跳水5.08%。截至发稿，该股报1.78美元/股，成交量193.226万股，换手率0.89%，振幅6.68%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体跌幅为1.27%。其相关个股中，Scilex Holding Company C/Wts 10/11/2027 、Procaps Group S.A. C/Wts 29/09/2026 、坎伯兰药业涨幅较大，Petros Pharmaceuticals, Inc.、Quantum Biopharma Ltd.、Painreform Ltd.较为活跃，换手率分别为69.18%、28.32%、18.89%，振幅较大的相关个股有Quantum Biopharma Ltd.、Im Cannabis Corp.、Bioage Labs, Inc.，振幅分别为53.90%、37.44%、28.05%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219042625a1f95415&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219042625a1f95415&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","AKBA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2491356319","title":"Akebia Therapeutics, Inc.盘中异动 下午盘股价大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491356319","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491356319?lang=zh_cn&edition=full","pubTime":"2024-12-13 03:20","pubTimestamp":1734031202,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日03时20分，Akebia Therapeutics, Inc.股票出现异动，股价大幅跳水5.21%。截至发稿，该股报1.82美元/股，成交量162.762万股，换手率0.75%，振幅4.95%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体跌幅为1.24%。其相关个股中，Scilex Holding Company C/Wts 10/11/2027 、Flora Growth Corp.、Incannex Healthcare Inc.涨幅较大，大自然药业、Flora Growth Corp.、Painreform Ltd.较为活跃，换手率分别为46.49%、18.34%、9.52%，振幅较大的相关个股有Gelteq Limited、Scilex Holding Company C/Wts 10/11/2027 、Sunshine Biopharma Inc C/Wts ，振幅分别为33.61%、26.09%、25.56%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213032002a1e9cf0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213032002a1e9cf0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","AKBA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2490863357","title":"Akebia Therapeutics, Inc.盘中异动 股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490863357","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490863357?lang=zh_cn&edition=full","pubTime":"2024-12-11 22:33","pubTimestamp":1733927593,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日22时33分，Akebia Therapeutics, Inc.股票出现波动，股价急速下挫5.05%。截至发稿，该股报1.88美元/股，成交量24.5064万股，换手率0.11%，振幅3.28%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体跌幅为0.22%。其相关个股中，Citius Oncology, Inc.、Avadel Pharmaceuticals Plc、Optinose, Inc.涨幅较大，Biofrontera Inc.、大自然药业、坎伯兰药业较为活跃，换手率分别为41.15%、7.02%、6.00%，振幅较大的相关个股有Bausch Health Companies Inc.、Biofrontera Inc.、Organogenesis Holdings Inc.，振幅分别为7.27%、5.85%、5.71%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223313ab6fcaf2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223313ab6fcaf2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AKBA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488973850","title":"Akebia Therapeutics, Inc.盘中异动 快速跳水5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488973850","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488973850?lang=zh_cn&edition=full","pubTime":"2024-12-04 04:17","pubTimestamp":1733257071,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日04时17分，Akebia Therapeutics, Inc.股票出现异动，股价急速下挫5.16%。截至发稿，该股报2.02美元/股，成交量259.044万股，换手率1.19%，振幅6.57%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体涨幅为0.91%。其相关个股中，Citius Oncology, Inc.、Medicus Pharma Ltd.、Sunshine Biopharma Inc C/Wts 涨幅较大，Citius Oncology, Inc.、大自然药业、Painreform Ltd.较为活跃，换手率分别为140.12%、39.18%、39.15%，振幅较大的相关个股有Citius Oncology, Inc.、Medicus Pharma Ltd.、Sunshine Biopharma Inc C/Wts ，振幅分别为116.67%、45.51%、32.53%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204041751a26a2928&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204041751a26a2928&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKBA","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akebia.com","stockEarnings":[{"period":"1week","weight":-0.0973},{"period":"1month","weight":-0.2766},{"period":"3month","weight":-0.1356},{"period":"6month","weight":-0.3419},{"period":"1year","weight":-0.637},{"period":"ytd","weight":-0.3665}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.0549},{"period":"3month","weight":0.0773},{"period":"6month","weight":0.127},{"period":"1year","weight":0.2743},{"period":"ytd","weight":0.0892}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Akebia Therapeutics, Inc.依法于2007年2月27日在特拉华州成立。该公司是一家致力于：基于缺氧诱导因子的新型生物性专有疗法的研发，肾脏疾病患者所需产品商业化应用的生物制药公司。HIF是人体内红细胞生成和潜在贫血治疗新机制的主要调节器。Akebia的候选主导产品AKB-6548作为一种每日一次的口服产品，已经成功完成2a期概念验证。研究表明AKB-6548可以在不需要透析的情况下安全有效地提高继发性贫血和慢性肾病患者的血红蛋白水平。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.00708},{"month":2,"riseRate":0.416667,"avgChangeRate":0.050021},{"month":3,"riseRate":0.5,"avgChangeRate":-0.064082},{"month":4,"riseRate":0.461538,"avgChangeRate":0.020155},{"month":5,"riseRate":0.538462,"avgChangeRate":0.019133},{"month":6,"riseRate":0.666667,"avgChangeRate":0.055123},{"month":7,"riseRate":0.5,"avgChangeRate":0.0412},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.035082},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.057186},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.11772},{"month":11,"riseRate":0.666667,"avgChangeRate":0.130076},{"month":12,"riseRate":0.5,"avgChangeRate":0.078804}],"exchange":"NASDAQ","name":"Akebia Therapeutics, Inc.","nameEN":"Akebia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akebia Therapeutics, Inc.(AKBA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Akebia Therapeutics, Inc.(AKBA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Akebia Therapeutics, Inc.,AKBA,Akebia Therapeutics, Inc.股票,Akebia Therapeutics, Inc.股票老虎,Akebia Therapeutics, Inc.股票老虎国际,Akebia Therapeutics, Inc.行情,Akebia Therapeutics, Inc.股票行情,Akebia Therapeutics, Inc.股价,Akebia Therapeutics, Inc.股市,Akebia Therapeutics, Inc.股票价格,Akebia Therapeutics, Inc.股票交易,Akebia Therapeutics, Inc.股票购买,Akebia Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akebia Therapeutics, Inc.(AKBA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Akebia Therapeutics, Inc.(AKBA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}